Regenxbio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
21.5%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$237.9Mnext fiscal year
FY EPS (est.)
-$2.79next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly150.5MTarget: Sufficient to fund operations into early 2027
RGX-202 Microdystrophin Expression Level (Week 12) Annually0.9Target: At least 10% microdystrophin expression in 90% or more of patients
Quarterly Revenue Quarterly6.4M
Watch Items
- FDA Regulatory Path and BLA Submission for RGX-202Trigger: Pre-BLA meeting with the FDA and subsequent BLA filing under the accelerated approval pathwayAction: Engage with the FDA to align on the correlation between microdystrophin expression and functional improvement (NSAA) to support accelerated approval.
- AbbVie Collaboration Milestone PaymentTrigger: First patient dosed in the Phase IIb portion of the NAAVIGATE study for diabetic retinopathyAction: Secure the $100 million milestone payment from AbbVie to extend the cash runway further into 2027.
- Resolution of FDA Complete Response Letter (CRL) and Clinical Holds on MPS ProgramsTrigger: Type A meeting with the FDA regarding RGX-121 (Hunter syndrome) and investigation of the RGX-111 serious adverse event (brain tumor)Action: Provide additional evidence from global MPS II experts to clarify the neuronopathic patient population and submit longer-term clinical data.
Research as of 19 Jun 2026